Organic Active Ingredients TRIZ Cases

Safinamide blocks voltage-gated sodium channels to treat myotonic disorders in patients resistant to mexiletine.

Stepwise nucleotide addition reduces dsRNA contaminants without causing product loss, improving pharmaceutical-grade RNA production efficiency.

Novel N-phenylbenzoxazolo-2-amine derivatives inhibit the BLT2 receptor, addressing the lack of effective small molecule inhibitors for cancer cell migration.

Nanosecond pulsed electric fields trigger calreticulin expression on tumor cells to stimulate an immune response.

Small molecule heterocyclic compounds induce erythroid differentiation and increase fetal hemoglobin production through targeted histone deacetylase inhibition.

Amide prodrugs modify functional groups to facilitate passage through the blood-brain barrier.

Novel low molecular weight compounds selectively inhibit O-GlcNAcase to modulate O-GlcNAc levels.

7-hydroxy-cannabidiol-C4 raises the seizure threshold to treat treatment-resistant epilepsy.

Acellular tissue fillers combine hyaluronic acid and decorin to reduce inflammatory responses and fibrosis during large volume tissue replacement.

Formula I-VI compounds correct trafficking defects to treat severe cystic fibrosis.

Knocking out the PHLDA3 gene reduces apoptosis and improves engraftment rates of pancreatic islets.

Targeting the 5' untranslated region via homology-independent integration resolves off-target effects while maintaining therapeutic specificity.

Anti-TIGIT antibodies bind TIGIT receptors on immune cells to prevent ligand interaction and trigger receptor internalization.

Segmented GCH1 gene testing combined with biopterin measurements resolves diagnostic precision limits in neuropsychiatric disease management.

KIR genotyping selects HNSCC patients for farnesyltransferase inhibitors, resolving variable treatment response and improving clinical efficacy.

D-allulose promotes UCP-1 expression to activate brown and beige adipocytes.

A variant human activin receptor IIB polypeptide uses targeted amino acid substitutions to bind myostatin, activin A, and GDF-11 ligands.

A polyion complex encapsulates messenger RNA within a PEG-block copolymer micelle for cellular delivery.

Genetic polymorphism analysis identifies antipsychotic-induced weight gain risk to enable personalized medication selection.

Targeting lactosylceramide synthesis reduces astrocyte activation to manage secondary progressive multiple sclerosis progression.

A crystalline monohydrate complex of compound A and L-proline forms through precipitation to yield a stable pharmaceutical material.

Autophagy-deficient trophoblast cells internalize serum protein aggregates for sensitive fluorescence detection using minimal sample volumes.

BCN057 activates WNT signaling to rescue intestinal stem cells, mitigating radiation-induced gastrointestinal syndrome.

A unit-type polyion complex delivers nucleic acids using a block copolymer with excess positive charges.

FB825 antibody targets membrane-bound IgE on B cells, reducing total serum levels and alleviating allergic symptoms with sustained suppression.

Targeted compounds reduce liver inflammation and fibrosis by inhibiting HSD17B13 activity.

Neurosteroids inhibit toll-like receptor signaling and enhance fractalkine activity to address non-responsive central nervous system inflammation.

Compound activates lipophagy to selectively decompose lipid droplets, reducing body weight without metabolic side effects.

Local delivery of aural pressure modulators maintains homeostasis while reducing systemic toxicities and discomfort.

Cholane-based ROR gamma modulators address insulin resistance and disease complications by regulating adipogenesis pathways.

Hydrocolloid microencapsulation shields vitamin K from mineral salt degradation during processing.

Intranasal racemic ketamine resolves the delay in traditional antidepressants by enabling rapid symptom reduction.

A cellulose composition incorporating cellooligosaccharides enhances particle binding properties.

Formula I heterocyclic compound degrades estrogen receptor via ubiquitin ligase recruitment.

Administers anti-inflammatory treatments before cancer vaccines to resolve chronic inflammation and enhance immune response.

Doppel-targeting molecules bind doppel to inhibit tyrosine kinase receptor signaling, sparing normal angiogenesis while suppressing tumor growth.

Amide derivatives of polycaffeoylquinic acids reduce IL-8 and TNF-alpha levels while maintaining cell viability.

Macrocyclic inhibitors reduce IDE activity to increase insulin stability and signaling in diabetes treatment.

Inhibiting TAK1 kinase halts epithelial-mesenchymal transition, reducing scarring in proliferative vitreoretinopathy and liver fibrosis.

Formula I compounds selectively inhibit NS5A function, addressing genetic heterogeneity and mutation challenges in Hepatitis C treatment.

Lactoferrin-loaded liposomes deliver active ingredients to ocular tissues via topical application.